- Home
- NTRP vs MTVA Comparison
NTRP vs MTVA Comparison
Compare NTRP & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRP
- MTVA
- Stock Information
- Founded
- NTRP 1985
- MTVA 2014
- Country
- NTRP United States
- MTVA United States
- Employees
- NTRP N/A
- MTVA N/A
- Industry
- NTRP
- MTVA
- Sector
- NTRP
- MTVA
- Exchange
- NTRP NYSE
- MTVA NYSE
- Market Cap
- NTRP 12.7M
- MTVA 15.1M
- IPO Year
- NTRP N/A
- MTVA N/A
- Fundamental
- Price
- NTRP $2.10
- MTVA $0.65
- Analyst Decision
- NTRP Hold
- MTVA Strong Buy
- Analyst Count
- NTRP 1
- MTVA 2
- Target Price
- NTRP $5.00
- MTVA $7.50
- AVG Volume (30 Days)
- NTRP 295.1K
- MTVA 632.7K
- Earning Date
- NTRP 06-10-2025
- MTVA 05-14-2025
- Dividend Yield
- NTRP N/A
- MTVA N/A
- EPS Growth
- NTRP N/A
- MTVA N/A
- EPS
- NTRP N/A
- MTVA N/A
- Revenue
- NTRP $501,422.00
- MTVA N/A
- Revenue This Year
- NTRP $354.28
- MTVA N/A
- Revenue Next Year
- NTRP $536.37
- MTVA N/A
- P/E Ratio
- NTRP N/A
- MTVA N/A
- Revenue Growth
- NTRP 186.93
- MTVA N/A
- 52 Week Low
- NTRP $1.39
- MTVA $0.63
- 52 Week High
- NTRP $8.50
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- NTRP 41.73
- MTVA N/A
- Support Level
- NTRP $1.72
- MTVA N/A
- Resistance Level
- NTRP $2.21
- MTVA N/A
- Average True Range (ATR)
- NTRP 0.22
- MTVA 0.00
- MACD
- NTRP 0.07
- MTVA 0.00
- Stochastic Oscillator
- NTRP 49.35
- MTVA 0.00
About NTRP NEXTTRIP INC
NextTrip Inc is a technology-driven platform delivering travel booking and travel media solutions. It provides individual and group travelers with vacations to popular and sought-after destinations in Mexico, the Caribbean, and across the world. NextTrip Media platform - Travel Magazine offers a social media platform for viewers to explore, educate, and share with friends their bucket list travel. The company is also launching an end-to-end content ecosystem that uses AI-assisted travel planning capturing advertising, building brand awareness, rewarding loyalty, and driving bookings.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.